ReviewCureus2025
Paraneoplastic Remitting Seronegative Symmetrical Synovitis With Pitting Edema: A Systematic Review of Case Reports and Observational Studies on Clinical Features, Treatment Response, and Outcomes.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is an uncommon inflammatory disorder that may occur as a paraneoplastic manifestation. To clarify its clinical profile, we reviewed published cases and observational studies reporting paraneoplastic RS3PE. A total of 120 patients were identified, including 40 individual case reports and four observational cohorts. The mean age was 69 years, and men accounted for approximately 70-80% of patients. Associated malignancies were diverse, with prostate (22%), lung (18%), and gastrointestinal cancers (16%) being the most frequent among solid tumors, alongside hematologic malignancies such as lymphoma and leukemia (12%). The hallmark clinical presentation was symmetrical synovitis of the hands and feet with pitting edema. Systemic features were common, including fever (36%), weight loss (28%), and fatigue (21%). Corticosteroid responsiveness varied: pooled analysis demonstrated an overall response rate of 78.4%, but outcomes differed by region. For example, two Japanese and U.S. cohorts reported remission in over 85% of patients, whereas a Chinese cohort described only 42.8% achieving remission. Relapses were frequent and often paralleled cancer progression, reinforcing the link between RS3PE activity and malignancy status. In 59.5% of cases, RS3PE was diagnosed simultaneously with cancer, while in others it preceded (25%) or followed (15%) cancer diagnosis. These findings suggest that paraneoplastic RS3PE is a distinct clinical entity and a sentinel marker of malignancy. Comprehensive cancer screening should be prioritized in affected patients, particularly older men with systemic symptoms or inadequate steroid response. Further multicenter research is needed to establish biomarkers and optimize management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.